Two new appointments at AAIPharma
This article was originally published in Scrip
AAIPharma (US) has appointed Dr Andreas Dreps senior vice-president of global clinical development services and Dr Ralf Wolter vice-president of clinical operations – Europe. Dr Dreps has more than 15 years' drug development experience, most recently leading the oncology therapeutic area at ICON. He has also worked at Merck KGaA, Rhône-Poulenc Rorer/Aventis and Bristol Myers-Squibb. Dr Wolter previously served as vice-president of clinical development at Apogenix, a German biotech company focused on oncology.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.